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Recently, aptamers began to emerge as therapeutics. In this issue of Chemistry & Biology, Famulok
and colleagues [1] present a twist on this concept, using an enzyme-inhibiting aptamer as a tool to
screen for small molecules that block HIV replication.For almost two decades now nucleic
acid receptors, commonly known as
aptamers, have been isolated from
large random-sequence libraries. These
molecules have been designed to
bind a wide range of interesting tar-
gets and have been applied in many
different ways in research areas such
as molecular sensing and affinity puri-
fication. Aptamers have also estab-
lished their potential to provide thera-
peutic benefits, with one aptamer
drug already on the market and others
currently in clinical trials. In this issue
of Chemistry & Biology, Famulok and
colleagues have cleverly combined
the ability of an engineered ribozyme
to act as a sensor with an aptamer
originally isolated for its therapeutic
potential [1]. The result of this ap-
proach was the isolation of a novel
small-molecule inhibitor for HIV re-
verse transcriptase (HIV-RT) that binds
an unexploited site on this highly
targeted protein.
The authors developed a high-
throughput assay to search for HIV-RT
inhibitors based on a rationally de-
signed allosteric hammerhead ribo-
zyme (shown schematically in Figure 1).
They combined the RNA-cleaving ri-
bozyme with an anti-HIV-RT aptamer.
The aptamer binding to its target
changes the conformation of the inte-
grated RNA molecule and results in
the inactivation of the ribozyme. In this
assay, established in a previous publi-
cation by Famulok’s group [2], the
ribozyme is in an inactive state when
aptamer is bound to its protein target
(Figure 1B). If the small molecule bind-
ing to the protein displaces the ap-
tamer, the ribozyme will become acti-
vated. The activation of the ribozyme
results in the cleavage of the substrate736 Chemistry & Biology 14, July 2007 ªRNA labeled with a fluorophore/
quencher pair, which releases the fluo-
rophore from quenching and gener-
ates a measurable signal (Figures 1A
and 1C).
Using functional nucleic acids as
sensor elements for screening is a rela-
tively new area that has begun to see
good success. Aptamers can be mod-
ified to produce many different types
of signals such as electrochemical,
acoustic, and piezoelectric [3]. How-
ever, fluorescence has become the
method of choice for high-throughput
approaches. In 2006, Elowe and col-
leagues isolated inhibitors of adeno-
sine deaminase in a screen of more
than 40,000 small molecules by using
a ‘‘structure switching’’ aptamer assay
that produced a fluorescent signal
in response to changing adenosine
concentrations [4]. Also in 2006, the
Famulok group published an aptamer
displacement assay that relied on fluo-
rescence polarization to screen for in-
hibitors of a cytohesin protein. These
inhibitors were then used to help eluci-
date the role of cytohesin proteins in
insulin signaling and diabetes [5].
While these methods relied on con-
formational changes in the aptamer
domain to generate a signal, enzy-
matic approaches using ribozymes
have also been employed. In 2004,
Archemix Corporation published an
assay that was suitable for screening
for inhibitors of protein kinases [6]. Re-
searchers seeking molecules that in-
teract with bacterial RNA gene regula-
tion elements, known as riboswitches,
have also looked at designing assays
for such systems. It is thought that
the ability of a small molecule to dis-
rupt the normal function of a riboswitch
could result in the misregulation of2007 Elsevier Ltd All rights reservedessential genes and thus such a mole-
cule may function as an antibiotic. This
idea was demonstrated earlier this
year using analogs of lysine that bind
the aptamer domain of lysine-respon-
sive riboswitches [7]. In 2006 the
Breaker group, a forerunner in the field
of riboswitches, and the Famulok
group, a forerunner in the field of ribo-
zyme-based screening, each devel-
oped a high-throughput assay for acti-
vators of the glmS riboswitch [8, 9].
While the assay from Breaker’s group
used a fluorescent resonance energy
transfer (FRET) mechanism [8], the
Famulok group made use of fluores-
cence polarization [9].
The Famulok group has been devel-
oping ribozyme-based screens since
2001 when they published an assay
for identifying inhibitors for the ham-
merhead ribozyme [10]. Their transi-
tion to allosteric ribozyme systems
has greatly expanded the arsenal of
targets that can be screened. Self-
cleaving ribozymes have been con-
verted, using both rational design and
selection processes, into allosteric
systems that are responsive to many
different regulating molecules [11].
The engineering and optimization of
aptamer displacement assays is there-
fore quite practical and broadly appli-
cable. The successful example in the
article presented here [1] will warrant
further attempts to take advantage of
this strategy.
The availability of high-quality ap-
tamers to relevant proteins is the key
to this approach becoming broadly
applicable. Aptamers have already
been isolated and characterized for
many attractive therapeutic targets
[12]. For example, thrombin-binding
aptamers with impressive in vitro
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finding makes the inhibitors like
SY-3E4 exciting as potential HIV
therapeutics.
Screening for site-specific inhibitors
is of great interest for those developing
antiviral treatments. Strategies to de-
velop aptamers that are specific to a
binding site on a protein [14] could be
translated into screens for small mole-
cules targeting that same site using
this aptamer displacement screening
strategy. Given the existence of many
aptamers for important viral proteins
[15], future endeavors might not be
long in waiting. The utility of this meth-
odology is clearly not limited to anti-
viral screening [5], and, in principle,
could be employed for any protein
or nonprotein target. One such area
is the development of antibiotics,
where similar resistance problems
can evolve, and site-specific screen-
ing would be an obvious benefit.
The use of DNA and RNA aptamers
and enzymes as sensors for high-
throughput small-molecule screening
is still a relatively new area of research.
However given the protocols in place
to isolate such molecules using cus-
tom-designed selection methods and
the impressive signaling properties
they can be made to display, it
appears to be a field with a bright
future.
Figure 1. An Inhibitor Screen via a Displacement Strategy Involving an Allosteric
Ribozyme, a Protein Target, and a Small Molecule
(A) An allosteric ribozyme containing a protein-binding aptamer element is capable of cleaving
a fluorogenic substrate labeled with a pair of fluorophore (F) and quencher (Q), generating a
fluorescent signal. (B) The formation of the aptamer-protein complex inactivates the ribozyme,
shutting down its signaling capability. (C) Introduction of a potential small-molecule inhibitor
that can compete with the aptamer for protein binding will lead to the displacement of the aptamer
from the same binding site, restoring the signal-producing activity of the ribozyme.characteristics have been examined
clinically for their potential as drugs
to prevent blood clotting. However,
the drawback preventing their wide-
spread use is their short lifetime
in vivo [12]. Issues of limited bioavail-
ability and inadequate lifetime are
recurring problems with aptamer
therapeutics that cannot always be
overcome by chemical modifications.
In the case of thrombin, and others
like it, the idea presented here offers
an excellent way to use these high-
quality aptamers to uncover small
molecules that have more desirable
drug-like properties.
The small-molecule inhibitors of
HIV-RT discovered using the allosteric
ribozyme screen [1], in particular
SY-3E4, are especially interesting be-
cause of the site they target. It had pre-
viously been shown that the aptamer
used in the screen binds the primer-template binding site of HIV-RT [13].
Using electrophoretic mobility shift
assays (EMSA), it was revealed that
SY-3E4 also targeted this same site
[1]. Clinically used inhibitors of HIV-
RT are largely nucleoside or nucleo-
tides aimed at mimicking the building
blocks used by HIV-RT to produce its
DNA product. No inhibitors currently
on the market have been shown to
function through blocking the primer-
template binding site. Therefore, the
molecules isolated in this screen po-
tentially represent a new class of in-
hibitors. Famulok and coworkers
illustrated the importance of this claim
by demonstrating that their inhibitors,
which disrupted HIV replication in cell
culture, were also effective against
multidrug-resistant strains of HIV [1].
It was previously shown that mutations
that overcame inhibition of aptamers
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Bone-related diseases, such as Pa-
get’s disease, osteoporosis, arthritis,
or cancer metastases, affect millions
of people worldwide. Bones are con-
stantly remodeled through the synthe-
sis of bone matrix by osteoblasts and
the resorption of bone by osteoclasts.
Osteoblasts and osteoclasts arise
from distinct cell lineages and matu-
ration processes—osteoclasts arise
from mesenchymal stem cells while
osteoclasts differentiate from hemato-
poietic monocyte/macrophage pre-
cursors [2]. One of the key factors
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mediating the process of osteoclast
formation known as osteoclastogene-
sis is receptor activator of nuclear
factor-kappaB (NF-kB) ligand (RANKL),
a member of the tumor necrosis factor
(TNF) family that has also been called
osteoclast differentiation factor, TNF-
related activation-induced cytokine,
and osteoprotegerin (OPG) ligand [3].
RANKL, protein expressed on the
surface of osteoblastic/stromal cells,
is directly involved in the differentiation
of monocyte macrophages into osteo-
clasts [4]. Mice with disruptions in the
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activity of a triterpene glycoside
of osteoclastogenesis, targeting
RANKL gene show a lack of osteo-
clasts, severe osteopetrosis, and de-
fective tooth eruption, indicating that
RANKL-induced osteoclastogenesis
is mediated through the cell surface
receptor RANK [5]. That RANK can
mediate osteoclastogenesis was first
demonstrated by Hsu and coworkers
in 1999 [6]. Further gene-deletion
analysis of RANK, RANKL, and TNF
receptor-associated factor 6 (TRAF6)
showed that these genes are positive
regulators of osteoclastogenesis [7],
whereas OPG, a decoy receptor for
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